Study title:
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin 2 and Interferon Alfa-2b. Journal of Clinical Oncology 1999; 17(3):968-975.Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin 2 and Interferon Alfa-2b. Journal of Clinical Oncology 1999; 17(3):968-975.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: TAMOXIFEN |
ATC code: L02BA01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|